MK-7684A Con o senza altre terapie antitumorali in partecipanti con tumori solidi selezionati (MK-7684A-005) (KEYVIBE-005)
Uno studio paniere multicentrico, in aperto, di fase 2 su MK-7684A, una co-formazione di vibostolimab (MK-7684) con pembrolizumab (MK-3475), con o senza altre terapie antitumorali in partecipanti con tumori solidi selezionati
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected advanced solid tumors. The primary hypothesis is that pembrolizumab/vibostolimab co-formulation is superior to pembrolizumab alone in terms of objective response rate or progression-free survival in participants with cervical cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
- Neoplasie cervicali uterine
- Neoplasie allo stomaco
- Neoplasie della vescica urinaria
- Carcinoma epatocellulare
- Neoplasie esofagee
- Neoplasie ovariche
- Neoplasie endometriali
- Carcinoma a cellule squamose della testa e del collo
- Colangiocarcinoma
- Neoplasie mammarie triplo negativo
- Neoplasie della cistifellea
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 1051)
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Cancer Centre ( Site 1056)
-
-
-
-
Araucania
-
Temuco, Araucania, Chile, 4800827
- James Lind Centro de Investigacion del Cancer ( Site 1404)
-
-
Region M. de Santiago
-
Santiago, Region M. de Santiago, Chile, 7500921
- FALP-UIDO ( Site 1401)
-
Santiago, Region M. de Santiago, Chile, 7510032
- Oncovida ( Site 1405)
-
Santiago, Region M. de Santiago, Chile, 8420383
- Bradfordhill-Clinical Area ( Site 1402)
-
-
-
-
Antioquia
-
Medellín, Antioquia, Colombia, 050030
- Fundacion Colombiana de Cancerología Clinica Vida ( Site 1422)
-
-
Atlántico
-
Barranquilla, Atlántico, Colombia, 080020
- Clinica de la Costa S.A.S. ( Site 1421)
-
-
Cundinamarca
-
Bogotá, Cundinamarca, Colombia, 111511
- Instituto Nacional de Cancerología-Clinical Oncology ( Site 1425)
-
-
Risaralda Department
-
Pereira, Risaralda Department, Colombia, 661001
- Oncologos del Occidente ( Site 1424)
-
-
Santander Department
-
Piedecuesta, Santander Department, Colombia, 681017
- Fundación Cardiovascular de Colombia ( Site 1423)
-
-
-
-
-
Seoul, Corea del Sud, 03080
- Seoul National University Hospital-Internal Medicine ( Site 1312)
-
Seoul, Corea del Sud, 03722
- Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1311)
-
Seoul, Corea del Sud, 05505
- Asan Medical Center ( Site 1313)
-
-
-
-
-
Paris, Francia, 75248
- Institut Curie ( Site 1152)
-
-
Auvergne-Rhône-Alpes
-
Lyon, Auvergne-Rhône-Alpes, Francia, 69373 Cedex 08
- CENTRE LEON BERARD-Medical oncology ( Site 1151)
-
-
Cote-d Or
-
Dijon, Cote-d Or, Francia, 21079
- Centre Georges François Leclerc ( Site 1155)
-
-
Herault
-
Montpellier, Herault, Francia, 34298
- Institut Regional du Cancer Montpellier ( Site 1157)
-
-
Paris
-
Villejuif, Paris, Francia, 94800
- Gustave Roussy-medicine departement ( Site 1153)
-
-
Vaucluse
-
Avignon, Vaucluse, Francia, 84000
- Sainte Catherine Institut du Cancer Avignon Provence-Oncologie médicale ( Site 1156)
-
-
-
-
-
Berlin, Germania, 12203
- Charite Universitätsmedizin Berlin Campus Benjamin Franklin ( Site 1171)
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Germania, 69120
- Universitaetsklinikum Heidelberg-Nationales Centrum für Tumorerkrankungen ( Site 1180)
-
Tübingen, Baden-Wurttemberg, Germania, 72076
- Universitaetsklinikum Tuebingen-Department of Internal Medicine VIII - Medical Oncology, ECTU, Pne
-
-
Bavaria
-
München, Bavaria, Germania, 81337
- Klinikum der Universität München Großhadern ( Site 1176)
-
-
North Rhine-Westphalia
-
Düsseldorf, North Rhine-Westphalia, Germania, 40225
- Universitaetsklinikum Duesseldorf-Gastroenterology, Hepatology and Infectiology ( Site 1172)
-
-
-
-
-
Osaka, Giappone, 541-8567
- Osaka International Cancer Institute ( Site 1323)
-
Tokyo, Giappone, 104-0045
- National Cancer Center Hospital ( Site 1322)
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Giappone, 464-8681
- Aichi Cancer Center Hospital ( Site 1324)
-
-
Chiba
-
Kashiwa, Chiba, Giappone, 277-8577
- National Cancer Center Hospital East ( Site 1321)
-
-
-
-
-
Haifa, Israele, 3109601
- Rambam Health Care Campus-Oncology ( Site 1141)
-
Jerusalem, Israele, 9112001
- Hadassah Medical Center-Oncology ( Site 1142)
-
Ramat Gan, Israele, 5265601
- Sheba Medical Center-ONCOLOGY ( Site 1144)
-
Tel Aviv, Israele, 6423906
- Sourasky Medical Center-Oncology ( Site 1143)
-
-
-
-
-
Milan, Italia, 20141
- Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (
-
Naples, Italia, 80131
- Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1134)
-
-
Lazio
-
Rome, Lazio, Italia, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Ginecologia Oncologica ( Site 1136)
-
-
Lombardy
-
Milan, Lombardy, Italia, 20132
- Ospedale San Raffaele-Oncologia Medica ( Site 1135)
-
-
Milano
-
Rozzano, Milano, Italia, 20089
- Istituto Clinico Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1138)
-
-
-
-
North Holland
-
Amsterdam, North Holland, Olanda, 1066CX
- Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1121)
-
-
South Holland
-
Rotterdam, South Holland, Olanda, 3015 GD
- Erasmus Medisch Centrum-Medical Oncology ( Site 1122)
-
-
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polonia, 02-781
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Oddzial Badan Wczesnych Faz ( Site 1101
-
-
Pomeranian Voivodeship
-
Gdansk, Pomeranian Voivodeship, Polonia, 80-952
- Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 1103)
-
-
West Pomeranian Voivodeship
-
Koszalin, West Pomeranian Voivodeship, Polonia, 75-581
- Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1104)
-
-
-
-
-
Madrid, Spagna, 28027
- Clinica Universidad de Navarra-Medical Oncology ( Site 1118)
-
Seville, Spagna, 41013
- HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO ( Site 1114)
-
-
Barcelona
-
Hospitalet, Barcelona, Spagna, 08907
- Instituto Catalan de Oncologia - Hospital Duran i Reynals-Medical Oncology ( Site 1113)
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spagna, 28223
- HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1117)
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spagna, 28034
- Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1111)
-
-
-
-
Alaska
-
Anchorage, Alaska, Stati Uniti, 99508
- Alaska Womens Cancer Care ( Site 1016)
-
-
California
-
Duarte, California, Stati Uniti, 91010
- City of Hope Comprehensive Cancer Center ( Site 1001)
-
Orange, California, Stati Uniti, 92868-3201
- University of California, Irvine (UCI) Health - UC Irvine Me-Chao Family Comprehensive Cancer Cente
-
-
Michigan
-
Detroit, Michigan, Stati Uniti, 48201
- Karmanos Cancer Institute ( Site 1007)
-
-
New Jersey
-
Basking Ridge, New Jersey, Stati Uniti, 07920
- Memorial Sloan Kettering - Basking Ridge ( Site 1023)
-
Middletown, New Jersey, Stati Uniti, 07748
- Memorial Sloan Kettering - Monmouth ( Site 1022)
-
Montvale, New Jersey, Stati Uniti, 07645
- Memorial Sloan Kettering - Bergen ( Site 1025)
-
-
New York
-
Commack, New York, Stati Uniti, 11725
- Memorial Sloan Kettering- Commack ( Site 1021)
-
Harrison, New York, Stati Uniti, 10604
- Memorial Sloan Kettering - Westchester ( Site 1020)
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center ( Site 1002)
-
Uniondale, New York, Stati Uniti, 11553
- Memorial Sloan Kettering - Nassau ( Site 1026)
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti, 74146
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1024)
-
-
South Dakota
-
Sioux Falls, South Dakota, Stati Uniti, 57104
- Sanford Cancer Center-Gynecologic Oncology ( Site 1015)
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Houston Methodist Hospital ( Site 1017)
-
-
-
-
-
Tainan, Taiwan, 704
- NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 1302)
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital-Oncology ( Site 1301)
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital ( Site 1305)
-
Taoyuan, Taiwan, 333
- Chang Gung Medical Foundation-Linkou Branch ( Site 1304)
-
-
-
-
-
Adana, Turchia (Türkiye), 01250
- Baskent University Dr. Turgut Noyan Research and Training Center ( Site 1201)
-
Ankara, Turchia (Türkiye), 06230
- Hacettepe Universitesi-oncology hospital ( Site 1209)
-
Ankara, Turchia (Türkiye), 06800
- Ankara City Hospital-Medical Oncology ( Site 1202)
-
Edirne, Turchia (Türkiye), 22030
- Trakya University-Medical Oncology ( Site 1207)
-
Istanbul, Turchia (Türkiye), 34303
- Acibadem Universitesi Atakent Hastanesi ( Site 1208)
-
Istanbul, Turchia (Türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1204)
-
-
Istanbul
-
Istanbul- Fatih, Istanbul, Turchia (Türkiye), 34098
- Istanbul Universitesi Cerrahpasa ( Site 1203)
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
One of the following histologically or cytologically confirmed, advanced (unresectable or metastatic) solid tumors:
- Squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
- Endometrial cancer
- Head and neck squamous cell carcinoma (HNSCC)
- Unresectable biliary adenocarcinoma (gallbladder or biliary tree [intrahepatic or extrahepatic] cholangiocarcinoma)
- Adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the gastroesophageal junction (GEJ).
- Triple-negative breast cancer (TNBC)
- Hepatocellular carcinoma (HCC)
- Urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra
- Ovarian cancer
- Gastric cancer
-
Measurable disease per RECIST v1.1 as assessed by BICR or local site investigator.
-
Adequately controlled blood pressure (BP) with or without antihypertensive medications.
-
Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART).
-
Male participants must agree to follow contraceptive guidance.
-
Female participants are not pregnant or breastfeeding, not a woman of child-bearing potential (WOCBP) or is a WOCBP and agrees to follow contraceptive guidance.
-
Adequate organ function.
Exclusion Criteria:
- History of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years.
- Prior therapy with anti-programmed cell-death (PD-1), anti-PD-L1, anti-PD-L2, or anti-T-cell immunoreceptor with Ig and ITIM domains (TIGIT) agent.
- Prior systemic anticancer therapy including investigational agents within 4 weeks before randomization/allocation.
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines are allowed.
- Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study medication.
- Active autoimmune disease that has required systemic treatment in past 2 years.
- Active infection requiring systemic therapy.
- Concurrent active hepatitis B and hepatitis C virus infection.
- History of allogenic tissue/solid organ transplant.
- Previous treatment with lenvatinib (for participants who will receive lenvatinib in their assigned treatment arm).
- Has clinically significant cardiovascular disease within 12 months from first dose of study intervention.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Pembrolizumab/Vibostolimab Co-Formulation
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion every 3 weeks (Q3W) up to 35 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy. |
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Altri nomi:
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
|
|
Sperimentale: Pembrolizumab
Participants receive pembrolizumab 200 mg via IV infusion Q3W up to 35 cycles. |
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
|
|
Sperimentale: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Endometrial Cancer Cohort)
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 20 mg once daily (qd) up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib. |
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Altri nomi:
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
Altri nomi:
|
|
Sperimentale: Pembrolizumab/Vibostolimab Co-Formulation + Lenvatinib (Hepatocellular Cancer Cohort)
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous IV infusion Q3W up to 35 cycles, plus lenvatinib 12 mg (body weight [BW] ≥60 kg) or lenvatinib 8 mg (BW <60 kg) qd up to 45 cycles. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Lenvatinib. |
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Altri nomi:
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD
Altri nomi:
|
|
Sperimentale: Pembrolizumab/Vibostolimab + 5-Fluorouracil + Cisplatin
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W, plus 5-fluorouracil (5-FU), plus Cisplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with 5-Fluorouracil + Cisplatin. |
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Altri nomi:
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
5-FU 800 mg/m^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles
Altri nomi:
Cisplatin administered via IV infusion
Altri nomi:
|
|
Sperimentale: Pembrolizumab/Vibostolimab Co-Formulation + Paclitaxel
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus paclitaxel as background therapy until meeting discontinuation criteria. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Paclitaxel. |
Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W
Altri nomi:
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
Paclitaxel administered via IV infusion at investigator's choice of dose
Altri nomi:
|
|
Sperimentale: Pembrolizumab/Vibostolimab Co-Formulation + Gemcitabine/Cisplatin
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus gemcitabine (until disease progression or unacceptable toxicity) and cisplatin (up to 8 cycles) as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Gemcitabine/Cisplatin |
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
Cisplatin administered via IV infusion
Altri nomi:
Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity |
|
Sperimentale: Pembrolizumab/Vibostolimab Co-Formulation+ Carboplatin/Paclitaxel/Bevacizumab
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus carboplatin, paclitaxel, and bevacizumab as local standard of care (SOC) background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Carboplatin/Paclitaxel/Bevacizumab. |
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
Paclitaxel administered via IV infusion at investigator's choice of dose
Altri nomi:
Carboplatin administered via IV infusion at investigator's choice of dose and frequency For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles |
|
Sperimentale: Pembrolizumab/Vibostolimab Co-Formulation + Capecitabine/Oxaliplatin
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W up to 35 cycles, plus capecitabine and oxaliplatin as background therapy. Participants receiving pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) will be given the option to transition to pembrolizumab monotherapy in combination with Capecitabine/Oxaliplatin. |
Pembrolizumab 200 mg administered via IV infusion Q3W.
Altri nomi:
Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles Oxaliplatin administered via IV infusion Q3W up to 35 cycles |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) in Cohort A1
Lasso di tempo: Up to approximately 24 months
|
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by blinded independent central review based on RECIST 1.1 was presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). The ORR was calculated using the Miettinen & Nurminen method stratified by prior bevacizumab use interactive voice response system (IVRS). ORR as assessed by BICR in Cohort A1 is presented. |
Up to approximately 24 months
|
|
Progression-Free Survival (PFS) Per RECIST 1.1 as Assessed by BICR in Cohort A1
Lasso di tempo: Up to approximately 24 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by BICR in Cohort A1 is presented. |
Up to approximately 24 months
|
|
ORR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Lasso di tempo: Up to approximately 24 months
|
ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR in selected solid tumors as assessed by investigator based on RECIST 1.1 is presented. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). Per protocol, Cohort A1 and Cohort I were excluded in the analysis. ORR as assessed by Investigator based on RECIST 1.1 is presented. |
Up to approximately 24 months
|
|
Progression Free Survival (PFS) Per RECIST 1.1 as Assessed by Investigator at 9 Months
Lasso di tempo: 9 months
|
PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-9 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 9 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 9 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented. |
9 months
|
|
PFS Per RECIST 1.1 as Assessed by Investigator at 12 Months
Lasso di tempo: 12 months
|
PFS is defined as the time from the first dose of study intervention to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS-12 is defined as the proportion of participants free of documented progression per RECIST 1.1 by investigator or death due to any cause at 12 months from the first dose of study intervention. Per protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS at 12 months as assessed by Investigator based on RECIST 1.1 in Cohort I is presented. |
12 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS) in Participants With Selected Solid Tumors
Lasso di tempo: Up to approximately 46 months
|
For Cohort A1 OS is defined as the time from randomization to death due to any cause. For Cohort A2 to Cohort J OS is defined as the time from the first dose of study intervention to death due to any cause. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. OS in selected solid tumors is presented. |
Up to approximately 46 months
|
|
PFS Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Lasso di tempo: Up to approximately 46 months
|
PFS is defined as the time from first dose of study treatment to the first documented PD or death due to any cause, whichever occurs first per RECIST 1.1 by Investigator for Cohort A2 to J. PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed Investigator in Cohort A2 to J is presented. |
Up to approximately 46 months
|
|
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR in Cohort A1
Lasso di tempo: Up to approximately 46 months
|
For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by BICR was presented for participants in Cohort A1. |
Up to approximately 46 months
|
|
DOR Per RECIST 1.1 as Assessed by Investigator in Participants With Selected Solid Tumors
Lasso di tempo: Up to approximately 46 months
|
For participants who demonstrate a confirmed Complete Response (CR: Disappearance of all target lesions) or confirmed Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by Investigator was presented. |
Up to approximately 46 months
|
|
ORR Per RECIST 1.1 as Assessed by Investigator in Cohort A1
Lasso di tempo: Up to approximately 24 months
|
ORR is defined as the percentage of participants who have a CR (Disappearance of all target lesions) or a PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by investigator based on RECIST 1.1 in Cohort A1 is presented. |
Up to approximately 24 months
|
|
PFS Per RECIST 1.1 as Assessed by Investigator in Participants in Cohort A1
Lasso di tempo: Up to approximately 24 months
|
PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PDPer protocol, RECIST 1.1 was modified to allow up to 10 target lesions total (up to 5 per organ). PFS was calculated using the nonparametric Kaplan-Meier method. PFS as assessed by Investigator based on RECIST 1.1 in Cohort A1 is presented. |
Up to approximately 24 months
|
|
Change From Baseline in Global Health Status/Quality of Life Score (European Organisation for Research and Treatment of Cancer Quality-of-Life Questionnaire Core 30 [EORTC QLQ-C30] Items 29 and 30) in Cohort A1
Lasso di tempo: Baseline and up to Week 12
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions "How would you rate your overall health during the past week?" and "How would you rate your overall quality of life during the past week?" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score in Cohort A1 is presented. |
Baseline and up to Week 12
|
|
Change From Baseline in Physical Functioning Score (EORTC QLQ-C30 Items 1-5) in Cohort A1
Lasso di tempo: Baseline and up to Week 12
|
The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to 5 questions about their physical functioning are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better quality of life. The change from baseline in Physical Functioning (EORTC QLQ-C30 Items 1-5) score in Cohort A1 is presented. |
Baseline and up to Week 12
|
|
Number of Participants Who Experienced One or More Adverse Events (AEs)
Lasso di tempo: Up to approximately 46 months
|
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that experienced at least one AE was reported for each treatment arm. |
Up to approximately 46 months
|
|
Number of Participants Who Discontinued Study Intervention Due to an AE
Lasso di tempo: Up to approximately 46 months
|
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE could therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a pre-existing condition that was temporally associated with the use of the Sponsor's product was also an AE. The number of participants that discontinued any study drug due to an AE was reported for each treatment arm. |
Up to approximately 46 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Direttore dello studio: Medical Director, Merck Sharp & Dohme LLC
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Malattie del sistema endocrino
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Malattie uterine
- Malattie genitali, femmina
- Neoplasie delle ghiandole endocrine
- Neoplasie della testa e del collo
- Malattie delle vie biliari
- Malattie del fegato
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie del fegato
- Malattie esofagee
- Malattie ovariche
- Malattie annessiali
- Neoplasie genitali, femmina
- Disturbi gonadici
- Malattie della pelle
- Malattie del seno
- Neoplasie urologiche
- Carcinoma
- Malattie della cervice uterina
- Neoplasie uterine
- Malattie della vescica urinaria
- Carcinoma, cellule squamose
- Malattie della cistifellea
- Neoplasie mammarie
- Neoplasie delle vie biliari
- Malattie della pelle e del tessuto connettivo
- Carcinoma a cellule squamose della testa e del collo
- Neoplasie allo stomaco
- Carcinoma, epatocellulare
- Neoplasie esofagee
- Neoplasie ovariche
- Neoplasie cervicali uterine
- Colangiocarcinoma
- Neoplasie della vescica urinaria
- Neoplasie mammarie triplo negativo
- Neoplasie endometriali
- Neoplasie della cistifellea
- Malattia di Parkinson 4, corpo di Lewy autosomico dominante
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Acidi nucleici, nucleotidi e nucleosidi
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Anticorpi, monoclonali, umanizzati
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Prodotti chimici inorganici
- Composti di cloro
- Composti di azoto
- Complessi di coordinamento
- Taxoidi
- Ciclodecani
- Diterpenes
- Deossictidina
- Citidina
- Nucleosidi di pirimidina
- Pirimidine
- Nucleosidi
- Uracile
- Pirimidinoni
- Composti di platino
- Deossiribonucleosidi
- Albumine
- Docetaxel
- Capecitabina
- Oxaliplatino
- Bevacizumab
- Paclitaxel legato all'albumina
- Gemcitabina
- Fluorouracile
- Carboplatino
- Paclitaxel
- Cisplatino
- pembrolizumab
- Lenvatinib
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 7684A-005
- MK-7684A-005 (Altro identificatore: MSD)
- jRCT2031210335 (Identificatore di registro: jRCT)
- KEYVIBE-005 (Altro identificatore: MSD)
- 2021-001009-56 (Numero EudraCT)
- U1111-1291-4290 (Identificatore di registro: UTN)
- 2023-505284-36-00 (Identificatore di registro: EU CT)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .